CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to JAZZ

Phase 3

Development Phase

1

Upcoming Catalysts

0

Historical Events

1

Regulatory Approvals

Upcoming Catalysts
What are catalysts?
Dec '26
JAZZPhase 2

Defibrotide Phase 2 Est. Readout

Defibrotide
Dec 2026~
CT.gov
00%
Competitive Landscape

0 competitors in Severe Hepatic Veno-Occlusive Disease

View Full Landscape
Drug Information

Target Indication

Severe Hepatic Veno-Occlusive Disease

Clinical Trial

NCT00358501

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Regulatory Approvals
EMA10/18/2013

Defitelio

Defitelio is indicated for the treatment of severe hepatic veno-occlusive disease (VOD) also known as sinusoidal obstructive syndrome (SOS) in haematopoietic stem-cell transplantation (HSCT) therapy. It is indicated in adults and in adolescents, children and infants over 1 month of age.

View on EMA
Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.